^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    23h
    CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Affiliated Hospital to Academy of Military Medical Sciences | Initiation date: Aug 2025 --> Apr 2026
    Trial initiation date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    5d
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=217, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2028 --> Jun 2027
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    9d
    A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Recruiting, Suzhou Immunofoco Biotechnology Co., Ltd | Phase classification: P1/2 --> P1
    Phase classification
    |
    CD19 positive • CD20 negative
    15d
    Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=6, Not yet recruiting, Fujian Medical University
    New P1 trial
    |
    IL4 (Interleukin 4)
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    20d
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (clinicaltrials.gov)
    P1, N=100, Recruiting, MSD R&D (China) Co., Ltd. | Trial primary completion date: Mar 2027 --> Sep 2028
    Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    CD19 positive
    22d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    22d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2028 --> May 2026 | Trial primary completion date: Jun 2027 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    PIT565
    26d
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial • IO biomarker
    |
    CD7 (CD7 Molecule)
    |
    CD19 positive
    26d
    Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, City of Hope Medical Center | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    CD19 positive
    |
    clonoSEQ
    |
    Venclexta (venetoclax) • cyclophosphamide • Blincyto (blinatumomab) • vincristine • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    29d
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    30d
    Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma. (PubMed, Am J Surg Pathol)
    On the basis of these findings, CD19 expression on HRS cells should not preclude the pathologic diagnosis of CHL, particularly in the context of mixed-cellularity or EBV+ disease. In addition, older patients with mixed-cellularity and/or EBV+ disease may represent a subgroup of patients with CHL who could benefit from CD19-directed therapies.
    Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD79A (CD79a Molecule)
    |
    CD19 positive
    1m
    PIC1 Injection Therapy for Relapsed/Refractory B-NHL (clinicaltrials.gov)
    P1, N=18, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • CD20 negative